
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is positioned for long-term success with its focus on providing genomic information at scale for pediatric and rare genetic disorders. With the potential for genomic testing to become the standard of care and advance precision medicine, GeneDx's offerings are well-positioned to drive improved outcomes and propel the company's growth. Despite short-term headwinds, the recently updated coverage policy and acquisition of Fabric Genomics provide a promising outlook for GeneDx's future profitability and potential market expansion.
Bears say
GeneDx Holdings is a market-leading company in the rare-disease testing industry, specializing in whole-exome and whole-genome sequencing for difficult-to-diagnose patients. However, the company has missed revenue expectations and lowered their guidance for fiscal year 2026, indicating potential challenges in scaling their business and expanding into other markets. Additionally, while the company's GUARDIAN study has shown promising results, it may take several more years before the data can be fully monetized and implemented into standard healthcare practices.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares